A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer.

Trial Profile

A Phase II Study of PEP02 as a Second Line Therapy for Patients With Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors PharmaEngine
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Aug 2013 Results have been published in the British Journal of Cancer, according to a Merrimack Pharmaceuticals media release.
    • 13 May 2013 Merrimack expects to report results from this trial in the second half of 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top